vimarsana.com

Latest Breaking News On - Mick readey - Page 3 : vimarsana.com

GSK : Jemperli (dostarlimab) plus Zejula (niraparib) combination significantly improved progression-free survival in primary advanced or recurrent endometrial cancer in RUBY Part 2 Phase III trial - Form 6-K -December 18, 2023 at 06:38 am EST

GSK : Japan s Ministry of Health, Labour and Welfare accepts Arexvy regulatory application to prevent RSV disease in adults aged 50-59 at increased risk - Form 6-K -December 12, 2023 at 06:09 am EST

GSK : Phase III RUBY trial of Jemperli (dostarlimab) plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer - Form 6-K -October 30, 2023 at 07:13 am EDT

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.